Skip to main content

Orion

Orion Oyj is a Finnish pharmaceutical enterprise that develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients globally. The company conducts its business through reportable operational segments comprising Pharmaceuticals (Innovative Medicines and Proprietary Products), Generics and Consumer Health, Animal Health, and API Operations. Its commercial medicine portfolio includes key drugs such as Nubeqa (darolutamide) for prostate cancer, Stalevo and Comtess for Parkinson's disease, and Easyhaler asthma inhalers. Principal revenue drivers consist of commercial sales of proprietary prescription medicines, generic pharmaceuticals, active pharmaceutical ingredients, alongside royalty income and milestone payments from alliance partners like Bayer. Orion serves broad global healthcare end markets encompassing hospital procurement bodies, retail pharmacies, veterinary clinics, healthcare providers, and patients across Europe and international markets. The enterprise holds a dominant market position as Finland's leading pharmaceutical company with a growing global footprint in targeted oncology treatments. Headquartered in Espoo, Finland, the company's Class A and B common shares are listed on Nasdaq Helsinki under ticker symbols ORNAV and ORNBV.

80 of the funds FundTelligence covers report a position in Orion.

Legal name
Orion OYJ
Sector
Health Care
Country
Finland
Funds holding it
80

Funds holding Orion

Showing the 8 largest of 80 funds holding it.

Loading...